Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
The Lancet Oncology.
Times cited: 1
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
Times cited: 4
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.
Journal of Clinical Oncology.
Times cited: 223